Centene Corporation CNC
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, Centene Corporation gets an algorithmic score of 63/100. It trades at 62.21 $, with a bullish technical trend (RSI 41.4) and 47.7% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (10.5% compound annual).
- Attractive free-cash-flow yield (14.1%).
- Low valuation (P/E 11.6).
- Low beta (0.24): defensive profile.
Weaknesses
- Low ROE (-20.4%).
- Thin net margin (-2.8%): vulnerable to costs.
Fundamentals
| Forward P/E | 11.63 |
| PEG | 0.75 |
| P/B | 1.36 |
| EV/EBITDA | 4.32 |
| P/S | 0.17 |
| ROE % | -20.36 |
| ROA % | 2.48 |
| Gross margin % | 11.42 |
| Operating margin % | 3.76 |
| Net margin % | -2.83 |
| Revenue growth % (y/y) | 4.60 |
| Revenue CAGR % | 10.45 |
| Debt/Equity % | 71.08 |
| Current ratio | 1.15 |
| FCF yield % | 14.06 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -3.9 % |
| 3 months | -3.1 % |
| 6 months | +95.6 % |
| YTD | +48.9 % |
| 1 year | +78.5 % |
| 3 years | -9.4 % |
| 5 years | -1.4 % |
Risk
| 1-year volatility | 47.7 % |
| Beta | 0.24 |
| 5-year max drawdown | -74.1 % |
| Sharpe 1A | 1.37 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.